Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: QLINE Medical Equipment/Supplies/Accessories | Small Cap | Q-Line Biotech Share Price
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: QLINE Medical Equipment/Supplies/Accessories | Small Cap | Q-Line Biotech Share Price
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.


Q-Line Biotech was originally incorporated as ‘POCT Services Private Limited’ on November 10, 2010 as a Private limited company. Subsequently, pursuant to a special resolution passed by the shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of the company was changed to ‘Q-Line Biotech Private Limited’. Further, pursuant to a special resolution passed by the shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, the company was converted from a private limited company to public limited company and consequently the name of the company was changed to ‘Q-Line Biotech Limited’.
The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and In Vitro Diagnostic (IVD) products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The core segments of operations of the company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).
Its key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics, Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc. It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. The company works on a B2B model and supplying most of its products to its customers which includes distributors, diagnostic service providers and hospitals.
Business area of the company
The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs.
Products and services of the company
Awards, accreditations and recognition
History and milestones
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: